Role of PCSK9 inhibitors in the management of dyslipidaemia

被引：5

作者：

Nair, Tiny ^{[1
]}

机构：

[1] PRS Hosp, Dept Cardiol, Trivandrum 695002, Kerala, India

来源：

INDIAN HEART JOURNAL | 2024年 / 76卷

关键词：

PCSK9; inhibitors; Dyslipidaemia; LDL; Familial hyperlipidemia; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; EVOLOCUMAB AMG 145; MONOCLONAL-ANTIBODY; SAFETY; LDL; EFFICACY; TRIAL;

D O I：

10.1016/j.ihj.2023.12.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Proprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with or without bempedoic acid or those intolerant to statins.

引用

页码：S44 / S50

页数：7

共 37 条

[1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].

Abifadel, M ;

Varret, M ;

Rabès, JP ;

Allard, D ;

Ouguerram, K ;

Devillers, M ;

Cruaud, C ;

Benjannet, S ;

Wickham, L ;

Erlich, D ;

Derré, A ;

Villéger, L ;

Farnier, M ;

Beucler, I ;

Bruckert, E ;

Chambaz, J ;

Chanu, B ;

Lecerf, JM ;

Luc, G ;

Moulin, P ;

Weissenbach, J ;

Prat, A ;

Krempf, M ;

Junien, C ;

Seidah, NG ;

Boileau, C .

NATURE GENETICS, 2003, 34 (02) :154-156

[2] New Drugs for Treating Dyslipidemia: Beyond Statins [J].

Ahn, Chang Ho ;

Choi, Sung Hee .

DIABETES & METABOLISM JOURNAL, 2015, 39 (02) :87-94

[3] Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics [J].

An, Dong ;

Wei, Xiaowei ;

Li, Hui ;

Gu, Hui ;

Huang, Tianchu ;

Zhao, Guifeng ;

Liu, Bo ;

Wang, Weilin ;

Chen, Lizhu ;

Ma, Wei ;

Zhang, Henan ;

Cao, Songying ;

Yuan, Zhengwei .

SCIENTIFIC REPORTS, 2015, 5

[4] Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) [J].

Bonaca, Marc P. ;

Nault, Patrice ;

Giugliano, Robert P. ;

Keech, Anthony C. ;

Pineda, Armando Lira ;

Kanevsky, Estella ;

Kuder, Julia ;

Murphy, Sabina A. ;

Jukema, J. Wouter ;

Lewis, Basil S. ;

Tokgozoglu, Lale ;

Somaratne, Ransi ;

Sever, Peter S. ;

Pedersen, Terje R. ;

Sabatine, Marc S. .

CIRCULATION, 2018, 137 (04) :338-350

[5] Low LDL cholesterol in African Americans resulting from frequent nonsense mutations in PCSK9 [J].

Cohen, J ;

Pertsemlidis, A ;

Kotowski, IK ;

Graham, R ;

Garcia, CK ;

Hobbs, HH .

NATURE GENETICS, 2005, 37 (03) :328-328

[6]

Cohen JC., 2018, A short history of PCSK9: from discovery to clinical trials

[7]

Deedwania P, 2018, LAT BREAK PHARM SCI

[8] Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia [J].

Dubuc, G ;

Chamberland, A ;

Wassef, H ;

Davignon, J ;

Seidah, NG ;

Bernier, L ;

Prat, A .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (08) :1454-1459

[9] Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs [J].

Everett, Brendan M. ;

Smith, Robert J. ;

Hiatt, William R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1588-1591

[10] Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment [J].

Gibbs, John P. ;

Slatter, J. Greg ;

Egbuna, Ogo ;

Geller, Michelle ;

Hamilton, Lisa ;

Dias, Clapton S. ;

Xu, Ren Y. ;

Johnson, Jessica ;

Wasserman, Scott M. ;

Emery, Maurice G. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (04) :513-523

← 1 2 3 4 →